Effects of edaravone on cardiac damage in valproic acid induced toxicity

Annals of Clinical and Laboratory Science

Volumn 45, Issue 2, 2015, Pages 166-172

  Emekli Alturfan, Ebru ^a   Alev, Burçin ^a   Tunali, Sevim ^b   Oktay, Sehkar ^a   Tunali Akbay, Tugba ^a   Ozturk, Leyla Koc ^a   Yanardag, Refiye ^b   Yarat, Aysen ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; MALONALDEHYDE; MYELOPEROXIDASE; NORPHENAZONE; SIALIC ACID; SUPEROXIDE DISMUTASE; THROMBOPLASTIN; VALPROIC ACID; ALKALINE PHOSPHATASE; N ACETYLNEURAMINIC ACID; PEROXIDASE; PHENAZONE; PHENYLMETHYLPYRAZOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SCREENING; ENZYME ACTIVITY; FEMALE; HEART INJURY; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANIMALIA; RATTUS;

ALKALINE PHOSPHATASE; ANIMALS; ANTIPYRINE; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; LIPID PEROXIDATION; MALONDIALDEHYDE; MYOCARDIUM; N-ACETYLNEURAMINIC ACID; PEROXIDASE; RATS; SODIUM-POTASSIUM-EXCHANGING ATPASE; SUPEROXIDE DISMUTASE; THROMBOPLASTIN; VALPROIC ACID;

EID: 84929304018     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007; 20: 499-502.
2. Hsieh LP, Huang CY. Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database. Epilepsy Res 2009;84: 21-27.
3. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009;18:483-91.
4. Terbach N, Williams RS. Structure-function studies for the panacea, valproic acid. Biochem Soc Trans 2009; 37: 1126-32.
5. Vasudev K, Mead A, Macritchie K, Young AH. Valproate in acute mania: is our practice evidence based? Int J Health Care Qual Assur 2012;25:41-52.
6. Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache 2012;52:636-647.
7. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3:5.
8. Zhang XZ, Li XJ, Zhang HY. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res Bull 2010;81:3-6.
9. Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol 2012;8: 81-91.
10. National Institutes of Health. Valproic Acid: MedlinePlus Drug Information. Last Accessed Nov 29 2012 http://www. nlm.nih.gov/medlineplus/druginfo/meds/a682412.html;2012.
11. Wells PG, McCallum GP, Chen CS, Henderson JT, Lee CJ, Perstin J, Preston TJ, Wiley MJ,Wong AW. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol Sci 2009;108: 4-18.
12. Cengiz M, Yuksel A, Seven M. The effects of carbamazepine and valproic acid on the erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children. Pharmacol Res 2000; 41, 423-425.
13. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998; 29: 195-201.
14. Raza M, Al-Bekairi AM, Ageel AM, Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: Time dependence of peroxidative injury. Pharmacol Res 1997;35: 153-157.
15. Kikuchi K, Kawahara K, Miyagi N,Uchikado H,Kuramoto T,Morimoto Y,Tancharoen S,Miura N,Takenouchi K,Oyama Y. Edaravone: A new therapeutic approach for the treatment of acute stroke. Med Hypothese 2010; 75: 583-585.
16. Kikuchi K, Miura N, Kawahara K, Murai Y, Morioka M, Lapchak P, Tanaka E. Edaravone (radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke (review). Biomed Rep 2013; 1: 7-12.
17. Kikuchi K, Kawahara K, Uchikado H, Miyagi N,Kuramoto T,Miyagi T, Morimoto Y,Ito T, Tancharoen S, Miura N. Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Exp Ther Med 2011; 2: 771-775.
18. Kikuchi K, Takeshige N, Miura N, Morimoto Y, Ito T, Tancharoen S, Miyata K, Kikuchi C,Iida N, Uchikado H. Beyond free radical scavenging: Beneficial effects of edaravone (radicut) in various diseases (review). Exp Ther Med 2012; 3: 3-8.
19. Beutler E. Gluthatione: red cell metabolism. A manual biochemical methods. New York: Grune and Stratton; 1975.
20. Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984; 105:328-37.
21. Habig WH, Jacoby WB. Assays for differentation of glutathione-s-transferases. Methods in Enzymol 1981; 77:398-405.
22. Aebi H. Catalase in vitro. In: Bergmeye HU, editor. Methods of enzymatic analysis. Wenheim: Verlag Chemie; 1974.
23. Paglia DE, Valentine WN. Studies on the quantitative and quantitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70, 158-168.
24. Mylorie AA, Collins H, Umbles C, Kyle J. Erythrocyte SOD activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82:512-520.
25. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 1959; 234: 1971-1975.
26. Walter K, Schült C. Acid and alkaline phosphatase in serum (two point method) In Methods of enzymatic Analysis Ed: Bergmeyer HU, 2nd ed. FL, p.856-886, 1974
27. Wei H, FrenkeL K. 1991, In vivo formation of oxidized DNA bases in tumor promoter-treated mouse skin. Cancer Res 1991; 51, 4443-4449.
28. Ridderstap AS, Bonting SL. Na+-K+-activated ATPase and exocrine pancreatic secretion in vitro. Am J Physiol 1969;217:1721-1727.
29. Ingram GIC, Hills M. Reference method for the one stage prothrombin time test on human blood. Thromb Haemostas 1976;36:237-238.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
31. Verrotti A, Scardapane A, Franzoni E, Manco R, Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res 2008; 78: 171-177.
32. Ashrafi MR, Shams S, Nouri M, Mohseni M, Shabanian R, Yekaninejad MS, Chegini N, Khodadad A, Safaralizadeh R. A probable causative factor for an old problem: Selenium and glutathione peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia 2007; 48: 1750-1755.
33. Schulpis KH, Lazaropoulou C, Regoutas S, Karikas GA,Margeli A, Tsakiris S, Papassotiriou I. Valproic acid mono - therapy induces DNA oxidative damage. Toxicology 2006;217: 228-232.
34. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; (13): 341-390.
35. Repetto M, Ossani G,Monserrat A, Boveris A. Oxidative damage: The biochemical mechanism of cellular injury and necrosis in choline deficiency. Exp Mol Pathol 2010; (88): 143-149.
36. Yuksel A, Cengiz M, Seven M, Ulutin T . Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies. J Child Neurol 2001;16(8):603-606.
37. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998; 29(4):195-201.
38. Cotariu D, Evans S, Zaidman JL, Marcus O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem Pharmacol 1990; 1;40(3):589-593.
39. Kürekçi AE, Alpay F, Tanindi S, Gökçay E, Ozcan O, Akin R, Isimer A, Sayal A. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 1995;36(6):600-604.
40. Doroshow J, Locker G, Myers C. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980; 65: 128-135.
41. Molina H, Garcia M. Enzymatic defenses of the rat heart against lipid peroxidation. Mech Ageing Dev 1997; 97(1): 1-7.
42. Julicher R, Tijburg L, Bast A, Koomen J. Decreased defense against free radical in rat heart during normal reperfusion after hypoxic, ischemic and calcium-free perfusion. Life Sci 1984;35: 1281-1288.
43. Raza M, Al-Bekairi AM, Ageel AM, Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res 1997; 35(2):153-157.
44. Olson MJ, Handler JA, Thurman RG. Mechanism of zonespecific hepatic steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the liver lobule. Mol Pharmacol 1986; 30(6):520-525.
45. Bork K, Gagiannis D, Orthmann A, Weidemann W, Kontou M, Reutter W, Horstkorte R. Experimental approaches to interfere with the polysialylation of the neural cell adhesion molecule in vitro and in vivo. J Neurochem 2007; 103;65-71.
46. Blaheta RA, Nau H, Michaelis M, Cinatl J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002; 9: 1417-1433.
47. Schwinger RHG, Bundgaard H, Müller-Ehmsena J, Kjeldsenb K. The Na, K-ATPase in the failing human heart. Cardiovasc Res 2003; 57: 913-920.
48. Schwinger RH, Wang J, Frank K, Müller-Ehmsen J, Brixius K, McDonough AA, Erdmann E. Reduced sodium pump alpha1, alpha3, and beta1-isoform protein levels and Na+,K+-ATPase activity but unchanged Na+-Ca2+ exchanger protein levels in human heart failure. Circulation 1999; 27;99(16):2105-2012.
49. Watanabe K, Morinaka Y, seki K, Watanabe T, Yuki S, Nishi H. Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone). Redox Rep 2003; 8: 151-155.
50. Ishikawa T, Esterbauer H, Sies H. Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J Biol Chem 1986; 261 (4): 1576-1581.
51. Mota A, Silva P, Neves D, Lemos C, Calhau C, Torres D, Martel F, Fraga H, Ribeiro L, Alçada MN, Pinho MJ, Negrão MR, Pedrosa R, Guerreiro S, Guimarães JT, Azevedo I, Martins MJ. Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res 2008; 41(7):600-609.
52. Hui M, Tenenbaum HC. New face of an old enzyme: alkaline phosphatase may contribute to human tissue aging by inducing tissue hardening and calcification. Anat Rec 1998; 253: 91-94.
53. Sanchez de Medina F, Martinez-Augustin O, González R, Ballester I, Nieto A, Gálvez J, Zarzuelo A. Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 2004; 68: 2317-2326.
54. Cannizzaro E, Albisetti M, Wohlrab G, Schmugge M. Severe bleeding complications during antiepileptic treatment with valproic acid in children. Neuropediatrics 2007; 38(1):42-45.
55. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005; 25:2273-2281.
56. Emekli-Alturfan E, Kasikci E, Yarat A. Peanuts improve blood glutathione, HDL-cholesterol level and change tissue factor activity in rats fed a highcholesterol diet. Eur J Nutr 2007;46:476-482.
57. Emekli-Alturfan E, Kasikci E, Yarat A. Tissue factor activities of streptozotocin induced diabetic rat tissues and the effect of peanut consumption. Diabetes Metab Res Rev 2007;23:653-658.